BioCorRx Inc.
BioCorRx Inc.
Your view on BICX
Overview
What the company does, where it operates, and who runs it.
About BioCorRx Inc.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Lourdes Felix
- Headquarters
- 2390 East Orangewood Avenue, Anaheim, CA, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Lourdes Felix
- Headquarters
- 2390 East Orangewood Avenue, Anaheim, CA, US
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States.
It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.
The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals.
The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioCorRx Inc., and the rating behind it. BICX last traded at $0.37; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioCorRx Inc.. Starting points for BioCorRx Inc.: EPS -$0.11, beta 0.39 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioCorRx Inc.. BioCorRx Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioCorRx Inc.. Trailing twelve-month EPS for BioCorRx Inc. stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioCorRx Inc.. BioCorRx Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioCorRx Inc. valued side by side against its closest peers. BioCorRx Inc. is measured against Medical - Care Facilities peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioCorRx Inc., and how their positions are changing. At a $7.0M market value, institutional positions materially move BioCorRx Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioCorRx Inc. executives and directors. Shares of BioCorRx Inc. have traded between $0.20 and $0.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioCorRx Inc.. BioCorRx Inc. is a $7.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioCorRx Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioCorRx Inc.. Coverage tracks BioCorRx Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.